Navigation Links
The Female Health Company to Host Third Quarter Conference Call on Friday, August 5, 2011
Date:7/29/2011

CHICAGO, July 29, 2011 /PRNewswire/ -- The Female Health Company (Nasdaq: FHCO) today announced that it will host an investor conference call to discuss its operating results for the third quarter and first nine months of FY2011 on Friday, August 5, 2011 at 11:00 a.m. Eastern Time (EDT).  The Company expects to report its operating results earlier the same day.

Shareholders and other interested parties may participate in the conference call by dialing 1-877-374-8416 (international participants dial 1-412-317-6716) and asking to be connected to "The Female Health Company Conference Call" a few minutes before 11:00 a.m. EDT on August 5, 2011.  A replay of the call will be available one hour after the call through 9:00 a.m. EDT on Monday, August 22, 2011 by dialing 877-344-7529 (international callers dial 412-317-0088) and entering the conference ID 10002775.  

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2), which is available in the U.S. and about 120 other countries globally.  The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in the U.S., Europe, Canada, Australia, South Africa, Japan, Spain, Greece, Turkey and the People's Republic of China, and pending in various countries.  The FC2 Female Condom® is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy.  The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.  

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings.  Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

For more information about The Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com .


'/>"/>
SOURCE The Female Health Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
2. The Female Health Companys Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms
3. The Female Health Company Declares 2nd Quarter Dividend of $0.05/share
4. The Me-Covery: Saatchi & Saatchi Wellness and Time Inc.s Health Brand Reveal Historic Shift in Female Consumer Behavior
5. Co-Promotion of a New Medical Device for Female Infertility Announced
6. The Female Health Company Receives Order for 3.5 Million FC2 Female Condoms for Distribution at 2010 World Cup
7. Second-Generation Female Condom is Now Available in the United States; FC2 Female Condom Will Cost 30 Percent Less than Predecessor
8. New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence
9. Female Health Company Receives Brazilian Order: Four Million FC Female Condoms
10. New Data Presented on the Renessa(R) Treatment for Female Stress Urinary Incontinence
11. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 Research and ... Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through ... their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production ... an in-depth assessment of the current trends in the ...
(Date:4/20/2017)... , April 20, 2017  CVS Pharmacy, ... today unveiled a new store design to enhance ... of healthier food, health-focused products and expanded beauty ... to help customers discover new offerings. Together with ... next evolution of the customer experience at CVS ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies ... to help with process innovation in drug formulation and manufacturing. CoreRx offers ... state-of-the-art analytical equipment in support of their development and manufacturing goals. , ...
(Date:4/25/2017)... Plains, NJ (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD is ... the treatment of acute or chronic problems, I focus on preventative care with all my ... If you have any questions, always feel free to contact my office and my trained ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® , a ... UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event ... the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair ...
(Date:4/24/2017)... ... April 24, 2017 , ... Michael Vick announced his retirement ... quarterback position. The former overall number one pick in the 2001 NFL Draft, to ... holds the record for the most career rushing yards by a quarterback (6,109) and ...
(Date:4/24/2017)... ... April 24, 2017 , ... NEPC Director Kevin Welner ... Education Research Award. The award honors scholars exemplary in their capacity to communicate ... who has demonstrated the capacity to deepen the public’s understanding and appreciation of ...
Breaking Medicine News(10 mins):